MRK - Merck & Co., Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
57.06
+0.72 (+1.28%)
As of 3:59PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close56.34
Open56.87
Bid57.11 x 5900
Ask57.12 x 4600
Day's Range56.63 - 57.17
52 Week Range53.63 - 66.80
Volume12,044,929
Avg. Volume11,130,498
Market Cap155.457B
Beta0.85
PE Ratio (TTM)55.24
EPS (TTM)1.03
Earnings DateFeb 2, 2018
Forward Dividend & Yield1.92 (3.46%)
Ex-Dividend Date2017-12-14
1y Target Est65.36
Trade prices are not sourced from all markets
  • Biopharma wins in Trump tax bill
    Yahoo Finance Videoyesterday

    Biopharma wins in Trump tax bill

    One sector that's poised to win big in the Trump tax bill, biopharma. Yahoo Finance's Seana Smith, Andy Serwer and Melody Hahm discuss.

  • Merck lagging this year, but charts show it's poised for ...
    CNBC Videos22 hours ago

    Merck lagging this year, but charts show it's poised for ...

    Carter Worth, Cornerstone Macro, discusses one lagging stock that could make a comeback.

  • Merck CEO on business conditions in China
    CNBC Videos6 days ago

    Merck CEO on business conditions in China

    Merck Chairman and CEO Stefan Oschmann weighs in on the business environment in China and how that has affected the pharmaceutical industry.

  • Capital Cube2 hours ago

    ETFs with exposure to Merck & Co., Inc. : December 12, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Merck & Co., Inc. Here are 5 ETFs with the largest exposure to MRK-US. Comparing the performance and risk of Merck & Co., Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)

  • 5 Blue-Chip Stocks to Buy in Mid-Turnaround
    InvestorPlaceyesterday

    5 Blue-Chip Stocks to Buy in Mid-Turnaround

    Blue-chip stocks are pushing higher again on Monday, as the combination of speculative excitement surrounding bitcoin mixes with the holiday spirit and seasonal tailwinds to keep prices marching higher.

  • Reutersyesterday

    Merck raises stakes in lung cancer as rivals close in

    Merck & Co Inc, maker of the only immunotherapy approved for patients newly-diagnosed with the most common type of lung cancer, could solidify its lead by playing the long game, even as rivals edge closer. Shares of Merck have fallen 10 percent since the drugmaker several weeks ago said it would make survival a main goal of a key lung cancer trial for immunotherapy Keytruda, extending the study by up to a year. In the meantime, Roche Holding AG has shaken up Wall Street expectations for the $15-billion (£11.3 billion) lung cancer market, showing its Tecentriq immunotherapy slows the spread of advanced lung cancer when combined with older treatments.

  • Business Wireyesterday

    FDA Accepts Supplemental Biologics License Application (sBLA), Assigns Priority Review to Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

    Merck , known as MSD outside the United States and Canada, today announced findings from the phase 2 KEYNOTE-170 trial investigating the use of KEYTRUDA® , the company’s anti-PD-1 therapy, in the cohort of patients with relapsed or refractory primary mediastinal large B-cell lymphoma , a type of non-Hodgkin lymphoma.

  • Reutersyesterday

    Roche: Tecentriq cocktail slows kidney cancer progression

    Combining Roche's Tecentriq immunotherapy with its older drug Avastin for the initial treatment of advanced kidney cancer reduced the risk of the disease worsening or of death in certain patients, the Swiss drugmaker said on Monday. The trial tested the combination against the current standard of care, Pfizer's Sutent, in patients with inoperable, locally advanced or metastatic renal cell carcinoma.

  • Reuters2 days ago

    Roche: Tecentriq cocktail slows kidney cancer progression

    Tecentriq, whose sales pale compared to established immunotherapies from Bristol-Myers Squibb and Merck & Co Inc, is a pillar of Roche's plan to replace revenue from its $20 billion-per-year trio of Avastin, Herceptin and Rituxan whose expiring patents have exposed them to cheaper competition. As a consequence, Roche is seeking to expand indications and patients eligible for treatment with its drug, which analysts see topping $4.6 billion in annual sales by 2023.

  • Merck & Co Inc (MRK): What You Have To Know Before Buying For The Upcoming Dividend
    Simply Wall St.3 days ago

    Merck & Co Inc (MRK): What You Have To Know Before Buying For The Upcoming Dividend

    Important news for shareholders and potential investors in Merck & Co Inc (NYSE:MRK): The dividend payment of $0.48 per share will be distributed into shareholder on 08 January 2018, andRead More...

  • GuruFocus.com5 days ago

    52-Week Company Lows

    Details the 52-week lows of the following companies: General Electric, Merck & Co, Schlumberger, Enterprise Products Partners, Kinder Morgan and Edison International

  • Why 2017 Was a Year to Forget for Merck & Co. Inc.
    Motley Fool5 days ago

    Why 2017 Was a Year to Forget for Merck & Co. Inc.

    Everything looked OK for the drugmaker until Merck delivered an unwelcome October surprise.

  • Business Wire6 days ago

    New England Journal of Medicine Publishes Phase 3 Clinical Study of PREVYMIS™ (letermovir), Merck’s New CMV Prophylaxis Medicine

    Merck & Co., Inc. , known as MSD outside the United States and Canada, today announced that the New England Journal of Medicine has published online the main results from the pivotal Phase 3 clinical study of PREVYMIS™ , the company’s new medicine for prophylaxis of cytomegalovirus infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant .